Related Experiment Video
Updated: Aug 10, 2026
08:56
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
Published on: April 7, 2023
Antiresorptive agents, raloxifene, and PHARMAC
1Health Care of Elderly, The Princess Margaret Hospital, Christchurch, New Zealand. NigelG@cdhb.govt.nz
The New Zealand Medical Journal
|March 15, 2006
Summary
Bisphosphonates are now the primary treatment for osteoporosis, replacing hormone therapy. Newer bisphosphonates and selective estrogen receptor modulators like raloxifene show promise for postmenopausal women, pending regulatory approval.
Area of Science:
- Bone Metabolism and Endocrinology
- Pharmacological Treatments for Osteoporosis
Background:
- Bisphosphonates have emerged as the cornerstone treatment for established osteoporosis, particularly after the decline in hormone replacement therapy use.
- Older bisphosphonate formulations and vitamin D analogues have had limitations in efficacy and dosing convenience.
Purpose of the Study:
- To review the current landscape of antiresorptive agents for osteoporosis treatment.
- To highlight the challenges and progress in accessing newer bisphosphonates and selective estrogen receptor modulators (SERMs).
Main Methods:
- Review of current osteoporosis treatment guidelines and drug availability.
- Analysis of the evaluation process for new osteoporosis medications by regulatory bodies.
Main Results:
- Newer generation bisphosphonates have faced challenges in availability, with a 10-year effort for improved access.
- Raloxifene, a SERM, is evaluated as a second-line agent for vertebral fracture prevention in postmenopausal women.
Conclusions:
- Continued efforts are needed to ensure timely access to effective osteoporosis treatments like newer bisphosphonates and raloxifene.
- Future availability of alternative antiresorptives and anabolic agents is anticipated with interest.
More Related Videos
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:28Drug-Receptor Interaction: Antagonist
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...